Motor Neurone Disease

Department of Health written question – answered at on 25 October 2017.

Alert me about debates like this

Photo of Thangam Debbonaire Thangam Debbonaire Opposition Whip (Commons)

To ask the Secretary of State for Health, what plans his Department has to assess the (a) clinical benefit and (b) value for money of Endaravone in extending the lifespan of people with motor neurone disease.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary of State for Health

We have assumed the Hon. Member is referring to edaravone (Radicava). Edaravone is not currently licensed or under assessment within the European Union for any indication and the Department therefore has no such plans. If the manufacturer seeks a marketing authorisation for edaravone in the United Kingdom or EU, it will be assessed for safety, efficacy and quality through the established licensing process and then considered through the topic selection process for possible assessment of clinical and cost effectiveness by the National Institute for Health and Care Excellence (NICE).

Where a drug or treatment has not been appraised by NICE, funding decisions should be made by the relevant National Health Service commissioner, based on an assessment of the available evidence and on the basis of an individual patient’s clinical circumstances.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.